The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Abstract
Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.7.1955 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11919263 Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer Richard R. LovexRichard R. LoveSearch for articles by this author Aron GoldhirschxAron GoldhirschSearch for articles by this author , John H. GlickxJohn H. GlickSearch for articles by this author , Richard D. GelberxRichard D. GelberSearch for articles by this author , Alan S. CoatesxAlan S. CoatesSearch for articles by this author , Hans-Jörg SennxHans-Jörg SennSearch for articles by this author Show More University of Wisconsin Comprehensive Cancer Center, Madison, WIInternational Consensus Panel on the Treatment of Primary Breast Cancer, St Gallen, Switzerland https://doi.org/10.1200/JCO.2002.20.7.1955 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse01042002In Reply:We thank Dr Love for his remarks drawing attention to the important role of adjuvant endocrine therapies, which are, as he rightly points out, a feature of the recent report1 of the 2001 St Gallen Consensus Panel. Some of his interpretations, however, seem to overlook the endocrine effects of chemotherapy, especially in older premenopausal women.The “historical accident” to which Love refers whereby adjuvant chemotherapy has become “essential” in the United States has not been as pervasive in other parts of the world. Workers in the United Kingdom2 and elsewhere3 have emphasized the investigation of appropriate endocrine therapies.Studies to dissect and define the optimal methods of delivering adjuvant endocrine therapy are currently of high research priority. Trials investigating the value of ovarian function suppression and the need for chemotherapy in addition to endocrine therapy will be activated shortly. The International Breast Cancer Study Group (IBCSG) has proposed a suite of three trials for premenopausal women with endocrine-responsive tumors, allowing participation by those with various preconceptions. The designs are as follows: 1. SOFT (Suppression of Ovarian Function Trial: IBCSG 24-02): For women remaining premenopausal after chemotherapy or not receiving chemotherapy; tamoxifen alone versus ovarian suppression plus tamoxifen versus ovarian suppression plus exemestane. 2. TEXT (Tamoxifen and Exemstane Trial: IBCSG 25-02): For women considered to require ovarian suppression with or without chemotherapy from the start of adjuvant therapy; tamoxifen plus gonadotropin-releasing hormone analog versus exemestane plus gonadotropin-releasing hormone analog. 3. PERCHE (Premenopausal ER-Positive Chemotherapy Trial: IBCSG 26-02): For women in whom the value of chemotherapy is uncertain; ovarian suppression plus tamoxifen or exemestane versus ovarian suppression plus tamoxifen or exemestane plus chemotherapy. The United States Intergroup, the Breast International Group, and other study groups will participate in some or all of these global clinical trials, which, when taken together, will address questions that we agree remain uncertain. Whether chemotherapy provides benefit to women with endocrine-responsive tumors in addition to combined endocrine treatment with ovarian function suppression and tamoxifen has until now proved difficult to study, though one recent small trial suggests that outcomes may be similar with or without chemotherapy after ovarian suppression.4Cost considerations may be dominant in some countries, whereas in others, women and their doctors will want information on optimal treatment, including both benefits and side effects.5,6 Meanwhile, the St Gallen Panel recommendations clearly recognize the importance of defining endocrine responsiveness in the selection of appropriate adjuvant therapy for early breast cancer treatment, either on or off study. The following reply, by Goldhirsch et al, was previously published in the February 1, 2002, issue of the Journal of Clinical Oncology. It is reprinted here for the convenience of the reader. Portions were changed by the authors to reflect updates to the trials to which the letter refers. 1. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Clin Oncol 19:: 3817,2001-3827, Link, Google Scholar2. Cancer Research Campaign Breast Cancer Trials Group: The effect of adjuvant tamoxifen: The latest results from the Cancer Research Campaign adjuvant breast trial. Eur J Cancer 28A:: 904,1992-907, Medline, Google Scholar3. Aebi S, Gelber S, Castiglione-Gertsch M, et al: Is chemotherapy alone adequate for young women with oestrogen-receptor-positi
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., & Hemminki, K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007133430201 · Cited by 4,114
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Parkin, D. M., Pisani, P., & Ferlay, J. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.33 · Cited by 3,376
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Estimates of the worldwide incidence of 25 major cancers in 1990
Parkin, Pisani, P., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>3.0.co;2-p · Cited by 2,037
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,423
Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321401 · Cited by 1,049
Fisher, B., Dignam, J., Wolmark, N., Wickerham, D. L., Fisher, E. R., Mamounas, E., Smith, R., Begovic, M., Dimitrov, N. V., Margolese, R. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05036-9 · Cited by 1,040
Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast Cancer
Early Breast Cancer Trialists' Collaborative Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198812293192601 · Cited by 933
Powles, T. (1998) · The Lancet · doi:10.1016/s0140-6736(98)05071-5 · Cited by 902
Fisher, B., Dignam, J., Wolmark, N., Mamounas, E., Costantino, J., Poller, W., Fisher, E. R., Wickerham, D. L., Deutsch, M., Margolese, R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.441 · Cited by 894
Veronesi, U. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04394-3 · Cited by 804
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Wood, W. C., Senn, H.-J., Glick, J. H., & Gelber, R. D. (1995) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/87.19.1441 · Cited by 689
Self-citationThe Influence of Margin Width on Local Control of Ductal Carcinoma in Situ of the Breast
Silverstein, M. J., Lagios, M. D., Groshen, S., Waisman, J. R., Lewinsky, B. S., Martino, S., Gamagami, P., & Colburn, W. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401902 · Cited by 673
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., Isaacs, C., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 672
Levine, M. N., Bramwell, V. H., Pritchard, K. I., Norris, B. D., Shepherd, L. E., Abu-Zahra, H., Findlay, B., Warr, D., Bowman, D., Myles, J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2651 · Cited by 617
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., & Senn, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3817 · Cited by 582
Self-citationOvarian ablation in early breast cancer: overview of the randomised trials
(1996) · The Lancet · doi:10.1016/s0140-6736(96)05023-4 · Cited by 561
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
(1994) · New England Journal of Medicine · doi:10.1056/nejm199407143310226 · Cited by 556
Narod, S. A., Brunet, J.-S., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S. L., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., de los Rios, P., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03258-x · Cited by 543
Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer
Fisher, B., Dignam, J., Emir, B., Bryant, J., DeCillis, A., Wolmark, N., Wickerham, D. L., Dimitrov, N. V., Abramson, N., Atkins, J. N., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.22.1673 · Cited by 521
Fisher, E. R., Dignam, J., Tan-Chiu, E., Costantino, J., Fisher, B., Paik, S., Wolmark, N., & for the National Surgical Adjuvant Breast Bowel Project (NSABP) Collaborating Investigators (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990801)86:3<429::aid-cncr11>3.0.co;2-y · Cited by 500
Schrag, D., Kuntz, K. M., Garber, J. E., & Weeks, J. C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362022 · Cited by 435
Klijn, J. G. M., Blamey, R. W., Boccardo, F., Tominaga, T., Duchateau, L., & Sylvester, R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.343 · Cited by 425
Veronesi, U., De Palo, G., Marubini, E., Costa, A., Formelli, F., Mariani, L., Decensi, A., Camerini, T., Del Turco, M. R., Di Mauro, M. G., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1847 · Cited by 419
Cauley, J. A., Lucas, F. L., Kuller, L. H., Stone, K., Browner, W., Cummings, S. R., & for the Study of Osteoporotic Fractures Research Group (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-4_part_1-199902160-00004 · Cited by 409
Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use
Osborne, C. K., Zhao, H. (., & Fuqua, S. A. W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3172 · Cited by 367
Bergh, J., Wiklund, T., Erikstein, B., Lidbrink, E., Lindman, H., Malmström, P., Kellokumpu-Lehtinen, P., Bengtsson, N.-O., Söderlund, G., Anker, G., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02841-5 · Cited by 339
Paszat, L. F., Mackillop, W. J., Groome, P. A., Boyd, C., Schulze, K., & Holowaty, E. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2625 · Cited by 302
Lindley, C., Vasa, S., Sawyer, W. T., & Winer, E. P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1380 · Cited by 296
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Aebi, S., Gelber, S., Castiglione-Gertsch, M., Gelber, R., Collins, J., Thürlimann, B., Rudenstam, C., Lindtner, J., Crivellari, D., Cortes-Funes, H., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02292-3 · Cited by 287
Self-citationFisher, B., Anderson, S., Tan-Chiu, E., Wolmark, N., Wickerham, D. L., Fisher, E. R., Dimitrov, N. V., Atkins, J. N., Abramson, N., Merajver, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.931 · Cited by 272
Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.
Ravdin, P. M., Siminoff, I. A., & Harvey, J. A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.515 · Cited by 262
Pagani, O., O’Neill, A., Castiglione, M., Gelber, R. D., Goldhirsch, A., Rudenstam, C.-M., Lindtner, J., Collins, J., Crivellari, D., Coates, A., et al. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10036-3 · Cited by 227
Self-citationLearning sentinel node biopsy: Results of a prospective randomized trial of two techniques
Morrow, M., Rademaker, A. W., Bethke, K. P., Talamonti, M. S., Dawes, L. G., Clauson, J., & Hansen, N. (1999) · Surgery · doi:10.1016/s0039-6060(99)70127-3 · Cited by 215
Colleoni, M., Bonetti, M., Coates, A. S., Castiglione-Gertsch, M., Gelber, R. D., Price, K., Rudenstam, C.-M., Lindtner, J., Collins, J., Thürlimann, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.584 · Cited by 197
Self-citationSCOTTISHCANCERTRIALSBREASTGROU (1993) · The Lancet · doi:10.1016/0140-6736(93)90812-u · Cited by 191
Lessons learned from BRCA1 and BRCA2
Zheng, L., Li, S., Boyer, T. G., & Lee, W.-H. (2000) · Oncogene · doi:10.1038/sj.onc.1203968 · Cited by 188
Zambetti, M., Moliterni, A., Materazzo, C., Stefanelli, M., Cipriani, S., Valagussa, P., Bonadonna, G., & Gianni, L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.37 · Cited by 186
Ursin, G., Henderson, B. E., Haile, R. W., Pike, M. C., Zhou, N., Diep, A. T., & Bernstein, L. (1997) · PubMed · Cited by 182
Quality-of-Life Scores Predict Outcome in Metastatic but Not Early Breast Cancer
Coates, A. S., Hürny, C., Peterson, H. F., Bernhard, J., Castiglione-Gertsch, M., Gelber, R. D., Goldhirsch, A., & for the International Breast Cancer Study Group (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3768 · Cited by 181
Self-citationHamilton, A., & Piccart, M. (2000) · Annals of Oncology · doi:10.1023/a:1008390429428 · Cited by 174
Fisher, B., Dignam, J., Tan-Chiu, E., Anderson, S., Fisher, E. R., Wittliff, J. L., & Wolmark, N. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.2.112 · Cited by 166
Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.
Pegram, M. D., & Slamon, D. (2000) · PubMed · Cited by 149
Love, R. R., Duc, N. B., Allred, D. C., Binh, N. C., Định, N. V., Kha, N. N., Thuân, T. V., Mohsin, S. K., Roanh, L. D., Khang, H. X., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.169 · Cited by 128
Self-citationSmith, T. J., & Hillner, B. E. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.771 · Cited by 99
Southey, M., Tesoriero, A., Andersen, C. R., Jennings, K. M., Brown, S., Dite, G., Jenkins, M., Osborne, R., Maskiell, J., Porter, L., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690008 · Cited by 98
Serum oestradiol and breast cancer risk.
Key, T. J. (1999) · Endocrine Related Cancer · doi:10.1677/erc.0.0060175 · Cited by 98
Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
Rebbeck, T. R. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00269-1 · Cited by 95
Jakesz, R., Hausmaninger, H., Samonigg, H., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)80701-1 · Cited by 72
Endocrine profile in breast cancer patients receiving chemotherapy
Mehta, R. R., Beattie, C. W., & Gupta, T. K. D. (1991) · Breast Cancer Research and Treatment · doi:10.1007/bf01834642 · Cited by 61
Cancer Research Campaign Breast, C. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90147-t · Cited by 30
HER-2 as a Prognostic, Predictive, and Therapeutic Target in Breast Cancer
Perez, E. A. (1999) · Cancer Control · doi:10.1177/107327489900600301 · Cited by 23
Continuation of the International Breast Cancer Intervention Study (IBIS).
Cuzick, J. M. (1998) · PubMed · Cited by 14
Cited by
Galimberti, V., Cole, B. F., Zurrida, S., Viale, G., Luini, A., Veronesi, P., Baratella, P., Chifu, C., Sargenti, M., Intra, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70035-4 · Cited by 1,233
Self-citationPawitan, Y., Bjöhle, J., Amler, L., Borg, A.-L., Egyhazi, S., Hall, P., Han, X., Holmberg, L., Huang, F., Klaar, S., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1325 · Cited by 831
Breast Cancer Before Age 40 Years
Anders, C. K., Johnson, R., Litton, J., Phillips, M., & Bleyer, A. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.03.001 · Cited by 791
Talarico, L., Chen, G., & Pazdur, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.175 · Cited by 727
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Self-citation
Metadata
- Authors
- Love, R. R., Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., & Senn, H.-J.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-04-01
- Volume
- 20
- Issue
- 7
- Pages
- 1955-1957
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131452141
- Cited by
- 414
- References
- 59
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.